Please login to the form below

Not currently logged in
Email:
Password:

Lixiana

This page shows the latest Lixiana news and features for those working in and with pharma, biotech and healthcare.

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Other directly-acting or ‘novel orally acting anticoagulants’ (NOACs) include Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa – which like Eliquis are Factor Xa inhibitors – and Boehringer

Latest news

  • The business case for patient engagement The business case for patient engagement

    More notably, Lixiana users are far less likely to promote the drug than Xarelto or Pradaxa users, despite having a similar level of confidence in the drug as Xarelto users and ... Are Lixiana users missing the confidence that Xarelto and Eliquis users

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

  • Daiichi Sankyo to shut down German antibody unit U3 Daiichi Sankyo to shut down German antibody unit U3

    Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for

  • Daiichi Sankyo cuts a swathe through US workforce Daiichi Sankyo cuts a swathe through US workforce

    The company is hoping that newer products such as novel oral anticoagulant (NOAC) Savaysa/Lixiana (edoxaban) will eventually fill the void left by Benicar, which is facing a challenging start as

  • Daiichi Sankyo licenses clot-busting antibody Daiichi Sankyo licenses clot-busting antibody

    The Japanese drugmaker is already a major player in the thrombosis market with products such as Eli Lilly-partnered antiplatelet drug Effient (prasugrel) and recently-introduced NOAC Lixiana (edoxaban).

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics